OpenPV Signal Explorer
FAERS disproportionality dashboard
Reaction

Gastrointestinal Hypomotility reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,202 reports · 65 co-occurring drugs

As of the last recalculation, Gastrointestinal Hypomotility appears in 2,202 FAERS reports alongside 65 co-occurring drug terms. The strongest observed disproportionality signal is ORAL SEMAGLUTIDE (PRR 80.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Oral Semaglutide48980.681.2
Dulaglutide54677.177.5
Tirzepatide36725.625.6
Empagliflozin16725.325.3
Insulin Degludec5623.123.2
Liraglutide11122.322.4
Dicyclomine Hydrochloride2818.818.8
Clozapine19916.416.4
Glimepiride6516.216.2
Linaclotide4014.414.4
Metformin Er 500 Mg38014.214.2
Metformin Er 750 Mg38014.214.2
Sucralfate Oral2114.114.1
Sucralfate Oral Suspension2114.014.1
Glipizide8714.014.0
Insulin Aspart9013.413.4
Metformin38412.112.1
Tizanidine2911.611.6
Lubiprostone1111.011.1
Sitagliptin689.29.2
Sevelamer Carbonate119.19.1
Sucralfate228.88.8
Lanreotide Acetate78.58.5
Meclizine Hcl 12.5Mg128.48.4
Meclizine Hcl 25Mg128.48.4
Meclizine Hcl 12.5 Mg128.48.4
Meclizine Hcl 25 Mg128.48.4
Meclizine Hydrochloride178.38.3
Chlorthalidone108.28.2
Meclizine148.28.2
Ropinirole138.08.1
Pioglitazone368.08.0
Cetiirizine357.97.9
Senna Leaf197.87.8
Theophylline Anhydrous107.77.7
Theophylline97.47.4
Insulin Glargine1807.47.4
Sennosides 8.6 Mg Tablets167.37.3
Senna167.27.2
Tobramycin Solution97.17.1
Benzonatate126.96.9
Tobramycin Sulfate96.96.9
Metoclopramide Hydrochloride556.96.9
Bupropion326.96.9
Human Insulin96.86.8
Linagliptin136.86.8
Famotidine806.66.6
Insulin Lispro936.66.6
Rosuvastatin1346.56.5
Duloxetine476.56.5
Glyburide166.36.3
Lisinopril1866.26.2
Norepinephrine65.35.3
Cenobamate44.54.5
Rimegepant Sulfate64.54.5
Icosapent Ethyl44.44.4
Tobramycin103.93.9
Paliperidone93.73.7
Ranolazine43.63.6
Asenapine Maleate33.33.3
Brivaracetam33.23.2
Canagliflozin82.52.5
Exenatide132.32.3
Erenumab-Aooe111.91.9
Galcanezumab-Gnlm41.21.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.